Impact of radiation and hepatitis virus infection on risk of hepatocellular carcinoma

Waka Ohishi, Saeko Fujiwara, John B. Cologne, Gen Suzuki, Masazumi Akahoshi, Nobuo Nishi, Masataka Tsuge, Kazuaki Chayama – 31 January 2011 – In cohort studies of atomic bomb survivors and Mayak nuclear facility workers, radiation‐associated increases in liver cancer risk were observed, but hepatitis B virus (HBV) and hepatitis C virus (HCV) infections were not taken strictly into account. We identified 359 hepatocellular carcinoma (HCC) cases between 1970 and 2002 in the cohort of atomic bomb survivors and estimated cumulative incidence of HCC by radiation dose.

C‐Src is required for complex formation between the hepatitis C virus–encoded proteins NS5A and NS5B: A prerequisite for replication

Andreas Pfannkuche, Katrin Büther, Juliane Karthe, Marion Poenisch, Ralf Bartenschlager, Mirko Trilling, Hartmut Hengel, Dieter Willbold, Dieter Häussinger, Johannes Georg Bode – 31 January 2011 – Hepatitis C virus (HCV) is a leading cause of chronic liver disease worldwide and establishes a persistent infection in more than 60% of infected individuals. This high frequency of persistent infection indicates that HCV has evolved efficient strategies to interfere with the adaptive and innate immune response and to occupy and use host cell infrastructure.

Pattern of bacterial and fungal infections in the first 3 months after pediatric living donor liver transplantation: An 11‐year single‐center experience

Hanaa Nafady‐Hego, Hamed Elgendy, Walid El Moghazy, Kazuhiko Fukuda, Shinji Uemoto – 31 January 2011 – Infection after pediatric living donor liver transplantation (LDLT) is a major cause of morbidity and mortality. Here, we sought to determine the incidence, timing, location, and risk factors for bacterial and fungal infections. We retrospectively investigated infection for 3 postoperative months in 345 consecutive pediatric patients (56.2% were females) who underwent primary LDLT at Kyoto University Hospital, Japan.

Portal inflow and pressure changes in right liver living donor liver transplantation including the middle hepatic vein

See Ching Chan, Chung Mau Lo, Kelvin K.C. Ng, Irene O.L. Ng, Boon Hun Yong, Sheung Tat Fan – 28 January 2011 – The middle hepatic vein may be included in right liver living donor liver transplantation (LDLT) to optimize hepatic venous outflow. We studied the graft's ability to relieve portal hypertension and accommodate portal hyperperfusion with portal manometry and ultrasonic flowmetry. Surgical outcomes with respect to portal hemodynamometry were also investigated.

Portopulmonary hypertension as an indication for combined heart, lung, and liver or lung and liver transplantation: Literature review and case presentation

Nicole E. Scouras, Takashi Matsusaki, Charles D. Boucek, Cynthia Wells, Erik A. Cooper, Raymond M. Planinsic, Erin A. Sullivan, Christian A. Bermudez, Yoshiya Toyoda, Tetsuro Sakai – 28 January 2011 – End‐stage liver disease with severe portopulmonary hypertension (PPHTN), which is refractory to vasodilator therapies, is a contraindication for isolated liver transplantation (LT) because of the high mortality rate.

Subscribe to